Highlights from ASH 2023 in Transplant-Eligible NDMM

EP: 1.The Evolving Landscape of Newly Diagnosed Multiple Myeloma

Now Viewing

EP: 2.Highlights from ASH 2023 in Transplant-Eligible NDMM

EP: 3.Advances in the Treatment of High-Risk MM

EP: 4.Role of Transplant and MRD in Newly Diagnosed MM

EP: 5.The Evolving Treatment Paradigm for Transplant Ineligible MM

EP: 6.Treatment of Multiple Myeloma at Early Relapse

EP: 7.Potential Role for CAR T-Cell Therapy in MM at Early Relapse

EP: 8.Updates on BCMA-Targeting Bispecifics in MM

EP: 9.Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

EP: 10.Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

EP: 11.Adverse Effects Related to Bispecifics in Multiple Myeloma

EP: 12.GPRC5D-Targeting Bispecifics in Multiple Myeloma

EP: 13.CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

EP: 14.Treatment Considerations and Sequencing in Multiple Myeloma

This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.

The experts discuss recent study results presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition regarding adding daratumumab to standard triplet induction, transplant consolidation, and maintenance therapy for newly diagnosed, transplant-eligible multiple myeloma patients.

The GRIFFIN trial showed improved stringent complete response rates with quadruplet induction including daratumumab vs triplet induction. The PERSEUS trial confirmed these findings in a larger phase 3 study, demonstrating improved progression-free survival at 4 years (84% vs 67%) and higher complete response and minimal residual disease negativity rates with quadruplet induction and maintenance including daratumumab. However, it is unclear if the benefit is from induction alone or requires continuous daratumumab therapy.

In real-world practice, consolidation post transplant and doublet maintenance is not universally used. The question remains if quadruplet induction alone is sufficient or if daratumumab should be incorporated into maintenance as well, especially for high-risk patients who may derive more benefit. Ongoing studies like the SWOG S1803 trial will provide more evidence regarding optimal maintenance strategies.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.